EMEA-000597-PIP03-15-M05
Key facts
| Invented name |
Betmiga
|
| Active substance |
Mirabegron
|
| Therapeutic area |
Uro-nephrology
|
| Decision number |
P/0187/2022
|
| PIP number |
EMEA-000597-PIP03-15-M05
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of neurogenic detrusor overactivity
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Astellas Pharma Europe B.V.
E-mail: contact.nl@astellas.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|